Novella Clinical has snagged its first high-profile partnership since being bought by CRO giant Quintiles, teaming up with biotech Scioderm to manage a mid-stage trial of the company's rare skin disease treatment.
France's Stallergenes has inked a deal worth up to $198 million with biotech DBV Technologies, partnering with the company to develop a treatment for birch allergy.
AstraZeneca has teamed up with Harvard University's Wyss Institute for Biologically Inspired Engineering to use the institute's "organs-on-chips" technology--miniature human organs made by 3D printing--to improve the way it tests drugs for humans.
Drug developer Amgen has reached out to KineMed with an eye on neurodegenerative biomarkers, paying to use the California biotech's platform to ferret out the causes of brain cell-killing disorders like Alzheimer's disease.
Germany-based Evotec AG has advanced an oncology molecule into preclinical development, raking in a €4 million ($5.4 million) milestone payment from partner Boehringer Ingelheim under a research pact.
The head of the pharma division, Stefan Oschmann, tells the Financial Times that the Darmstadt-based drug developer is looking to stretch its $1.5 billion annual research budget with some additional cost-sharing deals that might include private equity groups as well as other industry partners.
Quintiles is lending its research and analytics expertise to the Muscular Dystrophy Association, signing a deal to develop a massive registry of patient data that could help investigators develop new therapies.
Parexel International has inked a deal to pool its clinical trial data management service with a Japanese provider, teaming up to expand its share of the local market.
Antibody-drug conjugate superstar ImmunoGen has signed another agreement to lend its targeted drug technology to Novartis for an undisclosed cancer therapy.
Thursday night the biotech company offloaded the product, and its mesenchymal stem cell platform in regenerative medicine, to Australia's Mesoblast for $50 million in near-term cash and stock and up to $50 million more in milestones.